# INPLASY

Human Papillomavirus infection as a risk factor for Oral Leukoplakia- A systematic review and metaanalysis

INPLASY202540033

doi: 10.37766/inplasy2025.4.0033

Received: 10 April 2025

Published: 10 April 2025

## **Corresponding author:**

Divya Gopinath

drdivyagopinath17@gmail.com

#### **Author Affiliation:**

Ajman University.

# **ADMINISTRATIVE INFORMATION**

Support - Not applicable.

Gopinath, D; Taha, J.

Review Stage at time of this submission - Piloting of the study selection process.

Conflicts of interest - None declared.

**INPLASY registration number:** INPLASY202540033

**Amendments -** This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 10 April 2025 and was last updated on 10 April 2025.

## INTRODUCTION

Review question / Objective Do patients with oral leukoplakia have a higher rate of HPV infection than normal oral mucosal controls.

Condition being studied Oral eukoplakia.

### **METHODS**

Participant or population Human adults.

Intervention Leukoplakia.

Comparator Normal mucosa.

**Study designs to be included** Observational studies.

**Eligibility criteria** Case-control observational studies that assessed the prevalence of HPV in patients with oral leukoplakia specimens compared to controls were included.

**Information sources** PubMed, Scopus, and Wiley Library.

Main outcome(s) HPV infection rate.

Quality assessment / Risk of bias analysis New castle ottawa.

Strategy of data synthesis To calculate estimates of odds ratios and the corresponding 95% confidence intervals (CI). Subsequently, a pooled odds ratio (OR) estimate and its corresponding 95% confidence interval were computed using the random-effects model.

Subgroup analysis Population and PCR based.

**Sensitivity analysis** Removing studies with small sample size.

Country(ies) involved UAE.

**Keywords** Oral leukoplakia; HPV; OPMD; high risk HPV; premalignant.

## **Contributions of each author**

Author 1 - Divya Gopinath. Author 2 - Joud Taha.